HOOK

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Peters MalteDirector, Officer: Chief Executive Officer $45k54.3k shares SellAug 19, 2025 $20.7K25.2k shares $0.8217 --
Peters MalteDirector, Officer: Chief Executive Officer $73k79.5k shares SellJul 22, 2025 $26.8K29.2k shares $0.92 --
Coelho Mary TheresaDirector, Officer: EVP And CFO $52k56.3k shares SellJul 22, 2025 $12.5K13.6k shares $0.92 --
Coelho Mary TheresaDirector, Officer: EVP And CFO --69.9k shares Grant / ExerciseJul 22, 2024 Disclosure amount unavailable69.9k shares -- --
Peters MalteDirector, Officer: Chief Executive Officer --108.7k shares Grant / ExerciseJul 22, 2024 Disclosure amount unavailable108.7k shares -- --
Cassidy Sean ADirector $63k9.8k shares Grant / ExerciseJul 22, 2024 $63.1K9.8k shares $6.44 --

Trade HOOK

About HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc. operates as a clinical-stage biopharmaceutical firm dedicated to advancing immunotherapies for infectious diseases and various cancers. This endeavor is powered by its proprietary arenavirus platform. Its most advanced infectious disease program, HB-101, is in a randomized, double-blinded Phase II clinical trial, administered to patients awaiting kidney transplantation from cytomegalovirus-positive donors. In oncology, the company's lead candidates, HB-201 and HB-202, are undergoing Phase I/II clinical trials for human papillomavirus 16-positive cancers. Beyond these clinical programs, HOOKIPA's preclinical pipeline includes HB-300 for prostate cancer and HB-700, which aims to target mutated KRAS in pancreatic, colorectal, and lung cancers. The company has also established a strategic collaboration with Gilead Sciences, Inc. for preclinical research. This partnership focuses on evaluating potential vaccine products, leveraging HOOKIPA's replicating and non-replicating technology platforms, for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. Founded in 2011, HOOKIPA Pharma Inc. maintains its corporate headquarters in New York, New York.

CEO: Malte Peters
IPO Date: Apr 18, 2019

Market Data

Open: $1.15
High: $1.15
Low: $1.15
Volume: 0
Avg Volume: 12K
52W High: $1.55
52W Low: $0.811

Valuation

Market Cap: $14M
Enterprise Value: $-19M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-12M
Revenue: $9.7M
Net Income: $-14M
Cash: $37M
Debt: $135k

Events

EarningsAug 7